DNA Diagnostic Market Expects Huge Growth in the Developing Economies

The method of DNA diagnostics has revolutionized and helped in many ways to inspect human health. Needless to say, it helps to diagnose many diseases such as myogenic disorders, infectious diseases, and various forms of cancer. With regard to considerable increase in hazards, sprouting from different forms of viruses and diseases attacking life functions, it’s the need of an hour to develop innovative diagnostic devices to support evolving technologies. 

A report released by the World Bank the previous year suggested the fact that approximately 99% of patients who succumb to HIV/AIDS, malaria, or tuberculosis (TB) belong to the developing regions. This is a clear indication for vendors and developers in DNA diagnostics market to realize huge demand potential from these regions over the course of present decade. Interestingly, research and trial activities in these locations have been efficacious in identifying all regional factors to provide pertinent solutions. 

DNA diagnostics market and evolving economy
In a recent report compiled by the expert analysts at Allied Market Research (AMR), a clearly balanced estimation reveals that the Global DNA diagnostic market is expected to reach $19 billion dollar by 2020, growing at a CAGR of 9.8% during 2013 to 2020. Financial projections, which are suggestive of exponential expansion of involved business verticals, come through first-hand and credible corporate resources. 

According to the findings of the report, industry inputs indicate that the developed economies, such as North America and Europe, exhibit the tendency to retain their position in the diagnostic market. Developing economies, correspondingly, will gain increased capture of the worldwide DNA diagnostic market as a result of higher expenditure in healthcare services and large chunk of population staying undiagnosed. As per industry projections, Asia-Pacific would grow at an approximate CAGR of 12.2% throughout the forecast period. 

Next-generation sequencing for DNA diagnostics 
Progressive technologies form the key substance when it comes to advanced automated DNA diagnosis technologies such as next-generation sequencing, play a crucial role in diagnosing life-threatening diseases, such as cancer and HIV. The industry now witnesses a great deal of assistive interference from other relevant technologies as well. Organized data management for the vast sea of NGS data sets is one instance in this context. In this scenario, solution providers take charge of offering management services to assist the vendors in their R&D activities. Without the management services, the active inflow of huge data sets is rendered disorganized and thus meaningless. 

Startups, as well as established vendors, raise huge investor funding for running free genetic tests on voluntary patients. However, in exemplary cases, such as Strata Oncology, the focus lies within inviting huge enrolments in the first place for the sake of data gathering, and an ulterior motive of capturing some rare individual cases. This establishes a solid base for them to effectively plan and channelize their course of technique development.  

"While next-generation sequencing has had a significant impact on the diagnostic procedures and is set to gain momentum in the foreseeable future,” states AMR analyst Sharayu Dhabale. “Next-generation sequencing, not only reduces the cost of the sequencing technique, but increases overall throughput as well. It could efficiently assist the bridging of existing gap areas between traditional and personalized medications”, she adds. 

The right DNA diagnostics market approach
Population of patients suffering from genetically inherited, or modified, diseases keep growing in figures on a worldwide scale. Diagnosis of such shortcomings at an early stage initiates therapeutic handling minus the later stage complications, consequentially lowering the risk of fatalities due to the same. This develops a fortunate growth of demand space, wherein the DNA diagnostics market definitely grows at a steady rate. 

Personalized medicine, over the past couple of years has gathered distinct attention from research and development departments, given the extreme promise of targeting the right set of biological markers for precise diagnosis. It has been clarified by experts that no set of infecting agents remain same for individuals and are affected by their living environment. Drawing out a definitive pattern for similar cases, however, simplifies the assessment to some extent. The anticipation of approaching critical diseases with the right set of diagnostic tools, structurally reinforces the personalized treatment segment. 

Growth of the prominent diagnostic assay techniques, such as polymerase chain reaction (PCR), sequencing technology, microarray, in situ hybridization, and mass spectrometry technology, has laid a concrete groundwork for building profits in the DNA diagnostics market segment. Polymerase chain reaction (PCR) accounts for the largest share of DNA diagnostics market revenue. The streamlined study of sites where the diagnostic procedures are carried out provides further segmentation of the market. This gives us three basic groups – point of care, self-testing or over-the-counter (OTC), and diagnostic centers. Among these, diagnostic centers continue to single-handedly dominate the industry with more than 85% of population opting for it. In the current scenario, manufacturing startups stand a good chance at introducing quick-assay kits for the trailing self-testing or OTC, and point of care segment. 

Market players and their profit prospects
Key industrial players around the world, namely Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott Laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis, recognize strategic business moves being crucial to their market sustenance. Joint ventures for clinical testing and outsourcing of development & manufacturing techniques are some feasible strategies that shall help leading companies in the DNA diagnostics market to derive substantial progress.

Targeted next-generation sequencing, or tNGS, in recently proposed research ventures, focuses on adding its implementation extensively in prostate cancer management. Future prospects of such modifications would help designing immediate therapeutic modalities for patients suffering from prostate cancer. Analogous drivers, which boost current market size draws huge financial investments and stimulates competitive interests of existing as well as fresh business stakeholders.

 

Related Post